Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:BTMD NASDAQ:MDWD NASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$12.53+1.5%$10.70$5.01▼$18.70$88.00M0.22109,118 shs34,396 shsBTMDbiote$3.53+2.9%$3.75$2.76▼$6.98$174.52M1.19172,539 shs123,695 shsMDWDMediWound$16.48-0.8%$18.91$14.14▼$22.50$177.97M0.2574,521 shs115,657 shsORICOric Pharmaceuticals$10.47+0.9%$10.38$3.90▼$14.67$1.02B1.631.09 million shs760,086 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+2.41%-2.37%+6.84%+48.14%+62.37%BTMDbiote-0.29%+3.63%-11.83%-3.11%-45.38%MDWDMediWound-0.60%-1.43%-10.42%-23.50%-9.73%ORICOric Pharmaceuticals+1.47%+5.38%+2.57%+14.32%+0.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics4.5678 of 5 stars3.44.00.04.72.53.30.6BTMDbiote3.0682 of 5 stars3.34.00.00.02.01.71.3MDWDMediWound1.6912 of 5 stars3.41.00.00.01.90.80.6ORICOric Pharmaceuticals4.6421 of 5 stars4.51.00.04.43.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.80Moderate Buy$21.0067.60% UpsideBTMDbiote 2.50Moderate Buy$6.0069.97% UpsideMDWDMediWound 2.80Moderate Buy$32.2595.75% UpsideORICOric Pharmaceuticals 2.90Moderate Buy$17.6368.34% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ORIC, MDWD, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025MDWDMediWoundZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.008/14/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.008/13/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/12/2025ORICOric PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/7/2025BTMDbioteB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$8.00 ➝ $4.007/8/2025ORICOric PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.006/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$188.67M0.47N/AN/A($4.99) per share-2.51BTMDbiote$197.19M0.89$0.79 per share4.49($1.59) per share-2.22MDWDMediWound$20.22M8.81N/AN/A$1.86 per share8.86ORICOric PharmaceuticalsN/AN/AN/AN/A$3.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)BTMDbiote$3.16M$0.903.926.54N/A15.73%-21.00%18.26%11/11/2025 (Estimated)MDWDMediWound-$30.22M-$2.64N/AN/AN/A-142.18%-96.71%-39.73%N/AORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)Latest ATRA, ORIC, MDWD, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MDWDMediWound-$0.55-$1.23-$0.68-$1.23$5.68 million$5.71 million8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million8/6/2025Q2 2025BTMDbiote$0.06$0.10+$0.04$0.10$49.52 million$48.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A1.701.70BTMDbioteN/A0.980.74MDWDMediWoundN/A1.481.35ORICOric PharmaceuticalsN/A16.1316.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%BTMDbiote21.68%MDWDMediWound46.83%ORICOric Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%BTMDbiote24.00%MDWDMediWound9.20%ORICOric Pharmaceuticals5.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3307.02 million6.74 millionOptionableBTMDbiote19449.44 million37.57 millionNot OptionableMDWDMediWound8010.81 million9.81 millionOptionableORICOric Pharmaceuticals8097.12 million91.73 millionOptionableATRA, ORIC, MDWD, and BTMD HeadlinesRecent News About These CompaniesStocks To Watch: Oric Pharmaceuticals Sees RS Rating Jump To 824 hours ago | msn.comNuveen LLC Makes New Investment in Oric Pharmaceuticals, Inc. $ORICSeptember 3 at 3:39 AM | marketbeat.comDAFNA Capital Management LLC Purchases New Holdings in Oric Pharmaceuticals, Inc. $ORICSeptember 1 at 7:26 AM | marketbeat.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $17.63 Consensus Target Price from BrokeragesAugust 28, 2025 | americanbankingnews.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Moderate Buy" by BrokeragesAugust 27, 2025 | marketbeat.comThis ORIC Pharmaceuticals Insider Increased Their Holding In The Last YearAugust 24, 2025 | finance.yahoo.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Short Interest Down 45.0% in JulyAugust 20, 2025 | marketbeat.comORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief ...August 19, 2025 | bakersfield.comBORIC Pharmaceuticals: ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical OfficerAugust 19, 2025 | finanznachrichten.deORIC Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comOric Pharmaceuticals appoints Kevin Brodbeck CTOAugust 19, 2025 | msn.comEquities Analysts Offer Predictions for ORIC Q3 EarningsAugust 19, 2025 | marketbeat.comORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical OfficerAugust 18, 2025 | globenewswire.comWedbush Predicts Weaker Earnings for Oric PharmaceuticalsAugust 17, 2025 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Upgraded to Hold at Zacks ResearchAugust 17, 2025 | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock PriceAugust 16, 2025 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Given New $19.00 Price Target at HC WainwrightAugust 16, 2025 | marketbeat.comOric Pharmaceuticals' (ORIC) Buy Rating Reiterated at GuggenheimAugust 15, 2025 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Posts Earnings Results, Misses Expectations By $0.01 EPSAugust 14, 2025 | marketbeat.comLayoffs Continue Across Biotech Industry as More Companies Restructure and ReprioritizeAugust 14, 2025 | pharmexec.comPNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesJoby Aviation: Why a Historic Flight Outweighs Analyst DowngradesBy Jeffrey Neal Johnson | August 19, 2025Equal Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025Mercury Systems Up 27%: Financials Send Investors a Clear SignalBy Jeffrey Neal Johnson | August 14, 2025Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick?By Chris Markoch | August 28, 2025MarketBeat Week in Review – 08/18 - 08/22By MarketBeat Staff | August 23, 2025ATRA, ORIC, MDWD, and BTMD Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$12.53 +0.19 (+1.54%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.biote NASDAQ:BTMD$3.53 +0.10 (+2.92%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.MediWound NASDAQ:MDWD$16.48 -0.13 (-0.75%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Oric Pharmaceuticals NASDAQ:ORIC$10.47 +0.09 (+0.87%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
